Suchergebnisse - "Shahpari, Ramin"

PubPharm (8)

1

Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults : An immuno-bridging clinical trial

enthalten in: International immunopharmacology | 2024

von Tabarsi, P. | Mamishi, S. | Anjidani, N. | +11

2

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine : a phase 3 randomized placebo-controlled trial

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2023

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +9

3

Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients : A Single-arm Clinical Trial

enthalten in: Clinical therapeutics | 2022

von Nafar, M. | Mostafaloo, N. | Firouzan, A. | +10

4

Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination : A randomized placebo-controlled trial

enthalten in: Immunology | 2022

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +5

5

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine : a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

enthalten in: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2022

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +9

6

Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination : A randomized placebo‐controlled trial

enthalten in: Immunology | 2022

von Tabarsi, P. | Anjidani, N. | Shahpari, R. | +5

7

A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers

enthalten in: Expert opinion on investigational drugs | 2020

von Jamshidi, A. | Sabzvari, A. | Anjidani, N. | +2

8

A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers

enthalten in: Expert opinion on investigational drugs | 2020

von Jamshidi, A. | Sabzvari, A. | Anjidani, N. | +2

1
[1]